Skip to content
Search our Site
Search our site
Search our site
About the EPDA
Political affairs and policy
Resources and publications
All research papers
Search research papers
Mechanisms research papers
Melatonin Inhibits Manganese-Induced Motor Dysfunction and Neuronal Loss in Mice: Involvement of Oxidative Stress and ....
In conclusion, Mn treatment resulted in motor dysfunction and neuronal loss, possibly involving an interaction between oxidative stress and dopaminergic neurodegeneration in the substantia nigra and the striatum. Pretreatment with MLT attenuated Mn-induced neurotoxicity by means of its antioxidant properties and promotion of the DA system.
28 June 2014
Abrogation of α-synucleinmediated dopaminergic neurodegeneration in LRRK2-deficient rats
Study data suggest that knocking down LRRK2 may protect from overt cell loss by inhibiting the recruitment of chronically activated proinflammatory myeloid cells. These results may provide value in the translation of LRRK2-targeting therapeutics to conditions where neuroinflammation may underlie aspects of neuronal dysfunction and degeneration.
24 June 2014
Confirmation of the association between LRRK2 R1628P variant and susceptibility to Parkinson's disease in the Thai population
Authors confirm the association between p.R1628P and risk of developing PD in the appropriated sample-sized cohort. Certain LRRK2 variants appear to be generally distributed among East Asians, however, in widely different frequencies. In order to study role of such variants in PD, it should be carefully estimated the appropriate sample size.
23 June 2014
The expanding universe of disorders of the basal ganglia
Moreover, disorders that were thought to be caused by dysfunction of the basal ganglia only, such as Parkinson's disease and Huntington's disease, have diverse abnormalities distributed not only in the brain but also in the peripheral and autonomic nervous systems; this knowledge poses new questions and challenges. Authors discuss advances and the unanswered questions, and ways in which progress might be made.
19 June 2014
The genetics of Parkinson's disease: review of current and emerging candidates
Multiple genetic factors combine in different ways to increase or decrease risk, and several of these risk factors need to be identified in order to begin unraveling the causative pathways leading to the different forms of PD. In this review, we present current and emerging PD candidate genes to help explain the pathways leading to neurodegeneration.
17 June 2014
Antihypertensive Agents and Risk of Parkinson's Disease: A Nationwide Cohort Study
This study suggests centrally-acting dihydropyridine CCB use and high cumulative doses of ACEIs and ARBs may associate with a decreased incidence of PD in hypertensive patients. Further long-term follow-up studies are needed to confirm the potential beneficial effects of antihypertensive agents in PD.
09 June 2014
Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation
In this retrospective study, authors compared motor disease progression in Ashkenazi-Jewish (AJ) Parkinson's disease (PD) patients carrying the LRRK2*G2019S mutation with that of noncarriers.
05 June 2014
MUL1 acts in parallel to the PINK1/parkin pathway in regulating mitofusin and compensates for loss of PINK1/parkin
Together, these observations show that MUL1 acts in parallel to the PINK1/parkin pathway on a shared target mitofusin to maintain mitochondrial integrity. The MUL1 pathway compensates for loss of PINK1/parkin in both Drosophila and mammals and is a promising therapeutic target for PD.
04 June 2014
Serum uric acid and risk of dementia in Parkinson's disease
Here authors studied whether serum UA levels and the genetic variants related to its variability are associated with the presence of dementia in a cohort of patients with PD.
01 June 2014
Monoamine oxidase and α-synuclein as targets in Parkinson's disease therapy
In this work authors examine the biochemical properties of synthetic and natural molecules that are capable of interfering on both DA system (via monoamine oxidase inhibition) and AS fibrillation.
01 June 2014
Back to Top
Add page to PDF basket
Copyright © 2014 EPDA. All Rights Reserved.
Privacy and cookies